High Purity XCE Tirzepatide CAS 2023788-19-2 - Pharmaceutical Grade Peptide

XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist under development for type 2 diabetes treatment. This compound demonstrates significantly enhanced efficacy in both glucose regulation and weight management compared to single-receptor agonists.

The unique mechanism of XCE Tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, with particular affinity for GIP receptors. This dual action produces superior reductions in hyperglycemia while mimicking the natural actions of GIP at its receptor site.

Our XCE Tirzepatide is supplied as a white lyophilized powder with guaranteed purity exceeding 98%. Each batch undergoes rigorous HPLC testing to ensure quality and consistency for research applications.

Key pharmacological effects of XCE Tirzepatide include:

• Enhanced β-cell responses
• Reduced glucagon secretion from α-cells
• Decreased hepatic glucose output
• Appetite suppression through central nervous system action
• Delayed gastric emptying

This product is intended for research purposes only. Not for human consumption or diagnostic use. Proper laboratory safety protocols should always be followed when handling this material.